EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

Bristol Myers (BMY) announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investiga ...